Using Pandemic Data to Examine the Government’s Pandemic Prevention Measures and Its Support Policies for Vulnerable GroupsArticle Published on 2022-04-062023-07-08 Journal: Frontiers in Public Health [Category] COVID19(2023년), [키워드] COVID-19 Google pandemic prevention measures Vulnerable groups WHO [DOI] 10.3389/fpubh.2022.882872 PMC 바로가기
An open labeled, randomized, controlled clinical study to evaluate the efficacy of Torchnil capsules and Febcin tablet as add-on therapy for Covid-19 patientsResearch article Published on 2022-04-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 바이오마커, 신약개발, 임상, [키워드] addition Admission assessment Biomarker Biomarkers CAP Cap. Torchnil clinical Clinical management clinical study Clinical symptoms clinically conducted COVID-19 CPK D-dimer Day discharge disease Effect effective Efficacy Efficacy and safety evaluate Evidence group Hospital stay IL-6 improvement LDH material moderate disease objective Oxygen requirements Patient patients with moderate physical positive patient Randomized receive Result Safe screened Standard of care Symptoms Tab. Febcin Tablet therapy WHO [DOI] 10.1016/j.jaim.2022.100559 [Article Type] Research article
Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunitymRNA 항-COVID-19 백신 2회 접종 후 28주 만에 요양원에서 SARS-CoV-2 B.1.617.2(델타) 변종 발생: 면역 약화의 증거Article Published on 2022-04-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 48 hour 48 hours 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Anti-spike anti-Spike IgG Antibody Units B.1.617.2 B.1.617.2 SARS-CoV-2 variant binding antibody unit booster dose collected coronavirus coronavirus disease Coronavirus disease 2019 Coverage COVID-19 Delta diagnosed dose Effectiveness Evidence expressed Fisher exact test health worker health workers higher risk IgG Immunity index case Infection Italy Lineage material mRNA mRNA vaccine Neutralizing nursing home nursing home residents outbreak Quantitative Relative risk resident respiratory resulting risk RT-PCR SARS-CoV-2 SARS-COV-2 infection second dose Sequencing sera serum severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 severe disease titre vaccination Vaccine vaccine effectiveness variant waning immunity was determined was measured was performed WHO [DOI] 10.1016/j.cmi.2021.12.013 PMC 바로가기 [Article Type] Article
Forecasting of the efficiency of monoclonal therapy in the treatment of CoViD-19 induced by the Omicron variant of SARS-CoV2Research article Published on 2022-04-012022-10-05 Journal: Results in Physics [Category] 치료법, [키워드] administration Analysis biochemical Cell Characteristics COVID-19 criteria Delayed dynamics Efficiency faster Forecasting identify immune memory immune response infected cells information interval manuscript mathematical monoclonal monoclonal antibody Monolconal antibodies omicron parameter physiological Regression Regression learner SARS-CoV2 Sotrovimab Spread therapy threshold Treatment variant WHO World Health Organization [DOI] 10.1016/j.rinp.2022.105300 [Article Type] Research article
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients순환하는 디 펩 티딜 펩 티다 제 -4 효소 활성 감소는 Covid-19 입원 환자의 심각한 결과에 대한 예후이다.Observational Study Published on 2022-04-012022-08-31 Journal: Biomarkers in Medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] activity age characteristic circulating circulating DPP4 activity Combination Control COVID-19 COVID-19 disease death Decreased Dipeptidyl peptidase-4 disease disease severity Donor DPP4 enzyme activity group hospitalized COVID-19 patient hospitalized patient hospitalized patients indicated Inpatient Logistic regression material median Mortality outcome patients with COVID-19 plasma prognostic prognostic biomarker Prognostic marker receiver operating characteristic sampling SARS-CoV-2 serum serum sample serum samples severe COVID-19 disease severity significant decrease study group study groups T2DM were assessed were used WHO with COVID-19 [DOI] 10.2217/bmm-2021-0717 PMC 바로가기 [Article Type] Observational Study
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort studyObservational Study Published on 2022-04-012022-10-04 Journal: International Journal of Environmental Research an [Category] 임상, 치료법, [키워드] adjusted odds ratio administration Care chronic neurological disease clinical clinical decision Clinical practice cohort study Corticosteroid Corticosteroids COVID-19 Critical care Dementia demographics Dexamethasone discrepancy evaluate hospital Hydrocortisone identify Illness severity implementation independent Intervention ISARIC ISRCTN less likelihood Medical Research Council Methylprednisolone Older Patient patients with COVID-19 Prednisolone pregnant women Primary outcome Rate receive RECOVERY trial reduce mortality Registered significantly supplementary oxygen treated Treatment WHO [DOI] 10.1016/S2589-7500(22)00018-8 PMC 바로가기 [Article Type] Observational Study
Steroid therapy and antiviral treatment in SARS-CoV-2 pneumonia: clinical contexts and indicationsSARS-CoV-2 폐렴에서 스테로이드 요법 및 항바이러스 치료: 임상적 맥락 및 적응증Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] 28-day mortality Antiviral treatment benefit Clinical improvement clinical trial complications Corticosteroids Critically ill Critically ill patient critically ill patients decrease Dexamethasone Disease progression drug Effectiveness Fluid management group Health Organization higher risk include indication measure mechanical ventilation Meta-analysis Mortality oxygen Oxygen therapy Patient patients with COVID-19 per day performed Placebo RECOVERY trial reduction in Remdesivir requiring supplemental oxygen routine care SARS-CoV-2 Standard of care steroid therapy subgroup analysis supplemental oxygen supportive care systemic corticosteroid systemic corticosteroids Trial WHO with COVID-19 World Health Organization [DOI] 10.37201/req/s01.13.2022 PMC 바로가기 [Article Type] Review
Diagnostic precision of local and World Health Organization definitions of symptomatic COVID-19 cases: an analysis of Mexico’s capitalShort communication Published on 2022-04-012022-10-05 Journal: Public health [Category] 진단, [키워드] Analysis arise calculated Confirmed Contact COVID-19 COVID-19 case COVID-19 pandemic determine diagnostic Epidemiologic surveillance epidemiological Evidence FIVE Government identify Local Mexico Mexico City objective pandemic Precision Result sensitivity specificity symptomatic symptomatic cases the WHO while WHO World Health Organization [DOI] 10.1016/j.puhe.2022.02.010 [Article Type] Short communication
There is nothing exempt from the peril of mutation – The Omicron spike돌연변이의 위험에서 예외는 없다 - 오미크론 스파이크Review Published on 2022-04-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] ACE2 angiotensin angiotensin-converting enzyme 2 antibody approach approved binding caused Corona Corona virus COVID-19 COVID-19 therapy elevated entry pathway enzyme followed by Health Organization healthcare Healthcare system Interaction kinase inhibitors manuscript mutated Mutation omicron Omicron variant pandemic protease inhibitors RBD Receptor binding domain referred to researcher responsible risk spike Spike protein target the spike protein therapy Transmission Treatment Vaccine variant variant of concern verge Virus Disease VoC WHO World Health Organization [DOI] 10.1016/j.biopha.2022.112756 PMC 바로가기 [Article Type] Review
Elevated plasma levels of CXCL16 in severe COVID-19 patients중증 COVID-19 환자에서 CXCL16의 혈장 수준 상승Clinical Trial Published on 2022-04-012022-09-11 Journal: Cytokine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 임상, [키워드] association baseline benefit Cell cellular chemotaxis clinical trial Cohort collected controls COVID-19 CXCL16 CXCR6 defined determine disease elevated Genome-wide association studies homing hospitalized COVID-19 patient hospitalized patient hospitalized patients Immunopathogenesis Injury interact Ligand locus lung Lung infection Lungs motif P-value Pathogenesis Patient plasma plasma concentration plasma concentrations Plasma levels reported risk severe COVID-19 severe COVID-19 patient severity of COVID-19 Support susceptibility T cell T cells variant were assessed WHO Whole genome sequencing whole-genome sequencing [DOI] 10.1016/j.cyto.2022.155810 PMC 바로가기 [Article Type] Clinical Trial